Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Bolt Biotherapeutics Inc (NQ: BOLT ) 0.7390 UNCHANGED Streaming Delayed Price Updated: 4:00 PM EDT, Jun 24, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 100 Open 0.7390 Bid (Size) 0.7333 (10) Ask (Size) 0.7412 (1) Prev. Close 0.7390 Today's Range 0.7390 - 0.7390 52wk Range 0.7201 - 1.560 Shares Outstanding 8,709,974 Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News The Analyst Anxiety Index: 3 Stocks to Avoid as Uncertainty Grows May 24, 2024 Explore key stocks with analyst uncertainty to avoid amid contrasting global market highs and risky downgrades. Via InvestorPlace Why Bolt Biotherapeutics Shares Are Trading Lower By Around 34%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session May 15, 2024 Via Benzinga Performance YTD -36.29% -36.29% 1 Month -2.87% -2.87% 3 Month -38.42% -38.42% 6 Month -25.36% -25.36% 1 Year -42.71% -42.71% More News Read More 12 Health Care Stocks Moving In Wednesday's Intraday Session May 15, 2024 Via Benzinga This Accenture Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Today May 15, 2024 Via Benzinga Why Arcutis Biotherapeutics Shares Are Trading Higher By 29%; Here Are 20 Stocks Moving Premarket May 15, 2024 Via Benzinga 12 Health Care Stocks Moving In Wednesday's Pre-Market Session May 15, 2024 Via Benzinga Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday May 15, 2024 Via InvestorPlace BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q1 2024 May 14, 2024 Via InvestorPlace 12 Health Care Stocks Moving In Tuesday's After-Market Session May 14, 2024 Via Benzinga Bolt Biotherapeutics Reports First Quarter 2024 Results, Announces Strategic Pipeline Prioritization and Changes to Leadership Team May 14, 2024 From Bolt Biotherapeutics, Inc. Via GlobeNewswire 12 Health Care Stocks Moving In Wednesday's After-Market Session April 03, 2024 Via Benzinga BOLT Stock Earnings: Bolt Biotherapeutics Beats EPS, Beats Revenue for Q4 2023 March 21, 2024 Via InvestorPlace Bolt Biotherapeutics Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update March 21, 2024 From Bolt Biotherapeutics, Inc. Via GlobeNewswire Bolt Biotherapeutics to Present at the TD Cowen 44th Annual Healthcare Conference February 27, 2024 From Bolt Biotherapeutics, Inc. Via GlobeNewswire Pacira Appoints Frank D. Lee as Chief Executive Officer December 21, 2023 From Pacira BioSciences Via GlobeNewswire Bolt Biotherapeutics Enrolls First Patient in Phase 2 Clinical Study Evaluating BDC-1001 in Patients with HER2-Positive Breast Cancer Previously Treated with Enhertu® December 05, 2023 From Bolt Biotherapeutics, Inc. Via GlobeNewswire Bolt Biotherapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update November 09, 2023 From Bolt Biotherapeutics, Inc. Via GlobeNewswire Bolt Biotherapeutics to Present at Stifel 2023 Healthcare Conference November 07, 2023 From Bolt Biotherapeutics, Inc. Via GlobeNewswire 10 Biotech Stocks Below Cash Value with Key Catalysts on the Horizon: An Analysis October 23, 2023 Via ACCESSWIRE Bolt Biotherapeutics Presents Updated Clinical Data from Phase 1 Dose-Escalation Trial of BDC-1001 as Monotherapy and in Combination with Nivolumab in HER2-Expressing Tumors at ESMO 2023 Congress October 23, 2023 From Bolt Biotherapeutics, Inc. Via GlobeNewswire Bolt Biotherapeutics to Present Data at the Society for Immunotherapy of Cancer’s 2023 Annual Meeting October 18, 2023 From Bolt Biotherapeutics, Inc. Via GlobeNewswire Bolt Biotherapeutics Announces First Patient Dosed in Phase 1/2 Study of BDC-3042 in Patients with Advanced Cancers October 17, 2023 From Bolt Biotherapeutics, Inc. Via GlobeNewswire Bolt Biotherapeutics to Present New Clinical Data from Completed Phase 1/2 Dose-Escalation Trial of BDC-1001 in HER2-Expressing Solid Tumors at the ESMO Congress 2023 October 16, 2023 From Bolt Biotherapeutics, Inc. Via GlobeNewswire Why AERWINS Technologies Shares Are Trading Higher By Around 90%; Here Are 20 Stocks Moving Premarket October 02, 2023 Via Benzinga Bolt Biotherapeutics Receives Orphan Drug Designation for BDC-1001 for Treatment of Gastric Cancers September 28, 2023 From Bolt Biotherapeutics, Inc. Via GlobeNewswire Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.